Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan-Feb;34(1):369-379.
doi: 10.21873/invivo.11783.

Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry

Monika Bratova  1   2 , Bara Karlinova  3 , Jana Skrickova  1   2 , Milos Pesek  4   5 , Vitezslav Kolek  6   7 , Leona Koubkova  8   9 , Michal Hrnciarik  10   11 , Jana Krejci  12 , Magda Barinova  13 , Libor Havel  14 , Ivona Grygarkova  15 , Kristian Brat  16   2
Affiliations

Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry

Monika Bratova et al. In Vivo. 2020 Jan-Feb.

Abstract

Aim: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively.

Patients and methods: Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression-free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival.

Results: Survival at 2 years was more frequent in cohort 2015-16 compared to cohort 2011-12 (43.2% vs. 24% for adenocarcinoma; p<0.001 and 28.7% vs. 11.8% for squamous-cell lung carcinoma; p=0.002). Assignment to cohort 2015-16 and treatment multilinearity (two or more lines in sequence) were associated with higher probability of 2-year survival (hazard ratio=0.666 and hazard ratio=0.597; p<0.001). Comparison of 2-year survivors from both cohorts showed no differences.

Conclusion: Survival at 2 years probability in stage IIIB-IV NSCLC doubled between 2011-12 and 2015-16; advanced-stage NSCLC may be considered a chronic disease in a large proportion of patients.

Keywords: 2-year survival; Non-small cell lung cancer; chronic disease; modern-era treatment; personalized treatment.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest relevant to this study.

Similar articles

See all similar articles

Cited by

References

    1. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172(5):523–529. PMID: 15961694. - PubMed
    1. Cancer Facts Sheets: Lung Cancer. Globocan Cancer Observatory, World Health Organisation. 2018. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf Last accessed: July 23rd, 2019.
    1. Novotvary 2016, komplet (Cancer Incidence in the Czech Republic, 2016): Institute of Health Information and Statistics of the Czech Republic. 2016. Available at: http://www.uzis.cz/en/node/8139 Last accessed: August 18th, 2019.
    1. Pakkala S, Ramalingam SS. Personalized therapy for lung cancer: Striking a moving target. JCI Insight. 2018;3(15):120858. PMID: 30089719. DOI: 10.1172/jci.insight.120858. - PMC - PubMed
    1. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Updated efficacy and safety data and impact of the EML4–ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14(7):1233–1243. PMID: 30902613. DOI: 10.1016/j.jtho.2019.03.007. - PubMed

MeSH terms